William Burkoth

Bill Burkoth has been a director of Novocure since 2009 and has served on our nominating and corporate governance committee since 2015. Mr. Burkoth has worked for Pfizer Inc.’s Venture Investments Team since 2004, currently serving as Executive Director, where he has responsibility for making direct equity investments in private life-science companies on behalf of Pfizer Inc. Prior to joining Pfizer Inc., from 2002 to 2004, Mr. Burkoth worked in business development at the pharmaceutical companies Galileo Pharmaceuticals, Inc. and IntraBiotics Pharmaceuticals, Inc. From 1999 to 2002, Mr. Burkoth worked as an analyst at Bay City Capital, a life sciences venture capital firm. Mr. Burkoth currently serves as a director for private companies Biodesy, Inc., G-CON Manufacturing Inc., NeuMoDx Molecular, Inc., and RefleXion Medical Inc. Mr. Burkoth received a B.A. in chemistry from Whitman College and an M.B.A. from Columbia Business School.

Print Friendly, PDF & Email